(CercleFinance.com) – AstraZeneca announces that its Tagrisso (osimertinib) has been approved in Japan when combined with pemetrexed and platinum-based chemotherapy, as first-line treatment for adult patients with breast cancer. locally advanced or metastatic non-small cell lung (NSCLC) with specific EGFR mutations.
This approval is based on the results of a phase III trial which showed that this protocol reduced the risk of disease progression or death by 38% compared to Tagrisso alone.
Median progression-free survival was 25.5 months for the combination, compared to 16.7 months for Tagrisso alone. Overall survival results are promising but still immature.
Lung cancer is the leading cause of cancer deaths in Japan, with approximately 135,000 new cases of NSCLC each year, of which 36% have EGFR mutations.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
